Treace Medical Concepts, Inc.
Sector: Surgical & Medical Instruments & ApparatusIndustry: Medical - DevicesCountry: USExchange: Nasdaq
Analysis updated Nov 1, 2026.
Signal8 Summary
TMCI
Unprofitable with short cash runway
Snapshot
Treace Medical sells bunion correction devices with healthy gross margins, but heavy sales spending keeps the company deep in the red.
What's Happening Right Now
- : Treace reported Q2 revenue of $45.4 million, down 4% year-over-year, but raised full-year revenue guidance to $204-$212 million and improved its EBITDA loss outlook.
- : The company announced the first surgical case using its HyperPlate XM Dynamic Compression Locking Implant System, with full commercialization expected in Q3 2026.
Raise routes on file: no active ATM, effective shelf, S-1 or equity line in the filings read
AI dilution summary
The dominant contractual driver and its mechanism, then each further driver ranked.
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
Share count and cash history
Shares outstanding, potential dilution and cash over time
No warrants, convertibles, ATMs, shelfs or offerings were found in the filings read.
Know who's about to sell into your TMCI trade
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
